Correction to: Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era (Advances in Therapy, (2021), 38, 7, (3550-3588), 10.1007/s12325-021-01761-3)

Patricia K. Coyle; Anne Gocke; Megan Vignos; Scott D. Newsome

doi:10.1007/s12325-021-01967-5

Correction to: Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era (Advances in Therapy, (2021), 38, 7, (3550-3588), 10.1007/s12325-021-01761-3)

Patricia K. Coyle
, Anne Gocke
, Megan Vignos
, Scott D. Newsome

Neurology

Biogen IDEC
Johns Hopkins University

Research output: Contribution to journal › Comment/debate

1 Scopus citations

Abstract

The original article was published with an error regarding response to vaccination with ozanimod on page 3561 and in Table 4. The correct sentence and Table 4 are given below The few data available for other S1P receptor modulators suggest there can be some negative impact on vaccine response (145).

Original language	English
Pages (from-to)	822-830
Number of pages	9
Journal	Advances in Therapy
Volume	39
Issue number	1
DOIs	https://doi.org/10.1007/s12325-021-01967-5
State	Published - Jan 2022

Access to Document

10.1007/s12325-021-01967-5

Cite this

@article{25b5f62a615c4ca9b541b361491a1977,

title = "Correction to: Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era (Advances in Therapy, (2021), 38, 7, (3550-3588), 10.1007/s12325-021-01761-3)",

abstract = "The original article was published with an error regarding response to vaccination with ozanimod on page 3561 and in Table 4. The correct sentence and Table 4 are given below The few data available for other S1P receptor modulators suggest there can be some negative impact on vaccine response (145).",

author = "Coyle, \{Patricia K.\} and Anne Gocke and Megan Vignos and Newsome, \{Scott D.\}",

note = "Publisher Copyright: {\textcopyright} 2021, Springer Healthcare Ltd., part of Springer Nature.",

year = "2022",

month = jan,

doi = "10.1007/s12325-021-01967-5",

language = "English",

volume = "39",

pages = "822--830",

journal = "Advances in Therapy",

issn = "0741-238X",

number = "1",

}

TY - JOUR

T1 - Correction to

T2 - Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era (Advances in Therapy, (2021), 38, 7, (3550-3588), 10.1007/s12325-021-01761-3)

AU - Coyle, Patricia K.

AU - Gocke, Anne

AU - Vignos, Megan

AU - Newsome, Scott D.

PY - 2022/1

Y1 - 2022/1

N2 - The original article was published with an error regarding response to vaccination with ozanimod on page 3561 and in Table 4. The correct sentence and Table 4 are given below The few data available for other S1P receptor modulators suggest there can be some negative impact on vaccine response (145).

AB - The original article was published with an error regarding response to vaccination with ozanimod on page 3561 and in Table 4. The correct sentence and Table 4 are given below The few data available for other S1P receptor modulators suggest there can be some negative impact on vaccine response (145).

UR - https://www.scopus.com/pages/publications/85119276954

U2 - 10.1007/s12325-021-01967-5

DO - 10.1007/s12325-021-01967-5

M3 - Comment/debate

C2 - 34792786

AN - SCOPUS:85119276954

SN - 0741-238X

VL - 39

SP - 822

EP - 830

JO - Advances in Therapy

JF - Advances in Therapy

IS - 1

ER -

Correction to: Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era (Advances in Therapy, (2021), 38, 7, (3550-3588), 10.1007/s12325-021-01761-3)

Abstract

Access to Document

Other files and links

Fingerprint

Cite this